Can a Controlled Substances Agreement be signed electronically?

Yes. Electronic signatures are generally enforceable under the ESIGN Act (15 U.S.C. ch. 96) and UETA where adopted, provided intent, consent, attribution, and reliable record retention are met. For consumer‑facing healthcare records, follow ESIGN consent disclosure requirements.

Is notarization or witnesses required for validity?

Most states do not require notarization for treatment agreements. If a state or facility policy mandates notarization or witnesses, follow those rules. For remote notarization, confirm state RON statutes before relying on remote notary services.

How can a patient revoke the agreement?

Revocation should be handled in writing; record the revocation in the EHR. Note that revocation does not obligate continued prescribing and clinicians retain professional discretion to modify or stop controlled medications.

What privacy protections apply to the agreement?

The agreement contains protected health information and must be handled under HIPAA privacy and security rules. Use encrypted storage and limit access to authorized personnel; obtain any additional consents required for disclosures.

Who is authorized to sign on behalf of a patient?

Adults must sign personally. For minors or incapacitated adults, a legally authorized representative may sign per state law; document authority (power of attorney or guardianship) in the chart.

What if the prescribing clinician changes?

Document transfer of care, update the agreement or create a new one with the incoming clinician, and ensure continuity of monitoring and refill instructions in the medical record.

Electronic Signature
Templates
Legal
Controlled Substances Agreement

Controlled Substances Agreement

This template is fully customizable. Edit the text, fill out the fields, and send it for signature. Give it a try!

Controlled Substances Agreement

This Controlled Substances Agreement ("Agreement") is entered into on by and between Provider Name: , Provider Practice: , License No. (collectively "Provider"), and Patient Name: , Date of Birth: , Address: (collectively "Patient").

RECITALS

WHEREAS, Provider is authorized to prescribe controlled substances and manages treatment of pain and other conditions through the use of such medications; and

WHEREAS, Patient seeks treatment from Provider that may include the prescription of controlled substances, and Patient acknowledges the risks, potential for dependence, and obligations associated with such therapy; and

WHEREAS, Provider and Patient desire to set forth the terms, conditions, and monitoring procedures governing the prescription, use, and management of controlled substances to reduce risk and promote safe use.

NOW, THEREFORE, in consideration of the mutual promises contained herein, the parties agree as follows:

1. DEFINITIONS

"Controlled Substances" means medications regulated under federal and state law that have potential for abuse or dependence, including but not limited to opioid analgesics, benzodiazepines, stimulants, and other scheduled drugs.

2. PRESCRIBED MEDICATIONS

Controlled Substances to be Prescribed (list all current controlled substances) Primary Pharmacy (name and phone)

3. PATIENT OBLIGATIONS

3.1. Patient acknowledges receipt of information regarding risks and benefits of controlled substances, including the risk of addiction, overdose, and adverse drug interactions. Patient agrees to take medications only as prescribed by Provider.

3.2. Patient shall not: (a) sell, share, or distribute prescribed controlled substances; (b) obtain controlled substances from any other provider or source without first informing Provider; or (c) alter dosing without Provider approval.

3.3. Patient agrees to maintain one designated pharmacy for controlled substances and to provide Provider with a complete list of all medications, including over-the-counter drugs and supplements.

Emergency Contact (name and phone)

4. MONITORING, TESTING, AND REVIEW

4.1. Patient consents to periodic monitoring, which may include urine, blood, saliva, or hair testing, pill counts, review of pharmacy records, and review of prescription monitoring program data. Patient acknowledges that these measures are reasonable and necessary to ensure compliance.

4.2. Patient authorizes Provider to obtain prescription monitoring program records and to communicate with pharmacies and other health care professionals regarding Patient's prescription history. Patient understands that relevant findings indicating misuse or diversion may result in modification or cessation of controlled substance therapy.

4.3. Patient acknowledges that unexpected results from testing, evidence of unauthorized substances, refusal to submit to testing, evidence of diversion, or failure to comply with this Agreement may result in immediate discontinuation of controlled substances and referral to appropriate services.

5. REFILLS, LOST OR STOLEN MEDICATIONS

5.1. Refills will be provided only during scheduled appointments unless otherwise authorized in writing by Provider. Early refills will not be provided except in documented emergencies and at Provider's sole discretion.

5.2. Lost or stolen medication will not be routinely replaced. Provider may require police or insurance reports and reserves the right to decline replacement or to modify treatment.

6. TERMINATION OF THERAPY

6.1. Provider may discontinue or modify controlled substance therapy upon breach of this Agreement, evidence of diversion, violation of law, pregnancy, uncontrolled adverse effects, or clinical judgment that therapy is not safe or effective. Provider will attempt to coordinate tapering or transfer of care when clinically appropriate.

7. CONFIDENTIALITY AND INFORMATION SHARING

7.1. All clinical records are subject to applicable confidentiality laws. Patient consents to Provider sharing relevant treatment information with pharmacies, other health care providers, law enforcement, and state prescription monitoring programs as necessary for treatment, safety, or legal compliance.

8. RISKS, BENEFITS, AND ALTERNATIVES

8.1. Provider has explained the risks and benefits of controlled substance therapy and has discussed reasonable alternatives, including non-pharmacologic and non-controlled medication options. Patient acknowledges understanding and voluntarily accepts the risks.

9. LIABILITY AND INDEMNIFICATION

9.1. Patient understands that compliance with this Agreement does not guarantee a specific therapeutic result. Patient agrees to release and hold Provider harmless for adverse events resulting from misuse by the Patient or third parties, except to the extent caused by Provider's intentional misconduct or gross negligence.

10. NOTICES

10.1. All formal notices under this Agreement shall be in writing and delivered to the addresses below by personal delivery or by certified mail. Notice is effective upon receipt.

Provider Notice Address Patient Notice Address

11. AMENDMENT, WAIVER, COUNTERPARTS

11.1. This Agreement may be amended only by a written instrument signed by both parties. Failure by either party to enforce any provision shall not constitute a waiver of future enforcement. This Agreement may be executed in counterparts, each of which shall be deemed an original.

12. GOVERNING LAW; SEVERABILITY; ENTIRE AGREEMENT

12.1. Governing Law: This Agreement shall be governed by and construed in accordance with the laws of the state of without regard to conflict of laws principles.

12.2. Severability: If any provision of this Agreement is held invalid or unenforceable, the remaining provisions shall remain in full force and effect.

12.3. Entire Agreement: This Agreement contains the entire understanding between Provider and Patient regarding controlled substances and supersedes all prior agreements and understandings, whether oral or written, relating to the subject matter hereof.

ACKNOWLEDGMENTS

By signing below, Patient acknowledges that Patient has read and understands this Agreement, has had the opportunity to ask questions, and agrees to comply with all terms and conditions herein. Provider acknowledges that the terms of this Agreement were explained to Patient.

Patient Name:

By:

Date:

Provider Name:

By:

Date:

What a Controlled Substances Agreement Is and when it's used

A Controlled Substances Agreement is a written contract between a prescriber and a patient that documents treatment terms for controlled medications. It specifies medications, dosage limits, monitoring requirements (urine or blood testing), refill and early‑renewal policies, and conditions for continuation or termination. The agreement clarifies mutual responsibilities, informs patients about risks including dependence and adverse effects, and helps clinicians meet professional and regulatory expectations for safe prescribing.

Why a clear agreement matters for patient safety and compliance

A well‑written Controlled Substances Agreement reduces clinical ambiguity, creates documented informed consent, and supports compliance with prescribing standards and state monitoring programs. It assists clinicians during audits or investigations and improves patient understanding of treatment expectations and limits.

Who typically completes and signs this agreement

The agreement is normally completed during initial prescribing or a medication review visit and entered into the patient record.

Prescribing clinicians and their clinical staff for outpatient settings and pain clinics.
Patients who are starting or continuing treatment with schedule II–V controlled medications.
Pharmacies and clinic administrators for recordkeeping and refill verification.

Signatures are collected from both patient and prescriber; clinic staff may witness or upload to the electronic health record.

Primary signer roles and responsibilities

Prescribing Clinician

Physician, APRN, or PA who documents the treatment plan, establishes monitoring protocols, and retains authority to modify or terminate therapy based on clinical judgment and legal responsibilities. The clinician must verify identity, record consent, and keep the signed agreement in the medical record.

Patient / Recipient

The patient agrees to follow dosing instructions, submit to monitoring (drug testing, PDMP checks), not obtain overlapping prescriptions from other providers, and report adverse effects. The patient’s dated signature documents consent to the outlined terms and consequences for noncompliance.

Essential data fields to collect and store

Patient ID: MRN or DOB

Medication: Name and formulation

Dosage Limits: Daily or total limits

Prescriber Info: NPI and clinic

Monitoring: Testing schedule

Consent Status: Signed / revoked

Step-by-step: completing the Controlled Substances Agreement

Follow these steps during the patient visit to ensure the agreement is complete, legally sound, and properly recorded.

01

Prepare the form: Use clinic template and verify patient identity.
02

Complete clinical terms: Record medication, dose, monitoring, and refill rules.
03

Discuss and obtain consent: Review risks, alternatives, and patient responsibilities.
04

Sign and file: Collect signatures and upload to patient record.

Configuring an electronic workflow for the agreement

Set up a digital workflow that preserves audit trails and secures protected health information before launching.

Field	Recommended Setting
Signature Method	ESIGN with audit trail
Authentication	Two‑factor SMS or clinic portal login
Storage	Encrypted AES‑256 at rest
Notifications	Automated to patient and clinician

Where the signed agreement should be recorded and shared

After signatures are collected, place the agreement in official clinical and administrative locations for access and compliance.

Patient Chart: Upload to the EHR as a scanned or native document.
Pharmacy Record: Provide copy when required for dispensing validation.
PDMP: Use for prescription history checks, not as storage.
Clinic Archive: Retain copy in secure document management system.

Digital signing and platform considerations

Choose a signing platform that supports healthcare privacy and produces a verifiable audit trail.

File formats: PDF and DOCX accepted
Integrations: EHR and cloud storage
Security: TLS and AES encryption

Ensure the platform supports HIPAA (BAA available), audit logs, and integrations with systems like EHRs and cloud repositories.

Timing and review expectations for agreements

Establish clear review and documentation intervals to maintain safe prescribing and compliance.

Initial Agreement Date:

Date the agreement at first prescription or enrollment visit.

Follow-up Reviews:

Schedule periodic re‑evaluation, commonly every 3 months.

PDMP Checks:

Check state PDMP at each new prescription or as state law requires.

Drug Testing Window:

Specify testing frequency, e.g., baseline then random intervals.

Renewal/Refill Limits:

Document maximum refills and required visit intervals.

Common preparation errors to avoid

Leaving blanks in medication or dose fields which can cause pharmacy rejection and clinical confusion.
Using ambiguous language about refills or 'as needed' dosing without numeric limits, increasing overdose risk.
Failing to document monitoring expectations, such as PDMP checks and urine testing schedules.
Collecting signatures without verifying identity or retaining a verifiable audit trail for electronic signatures.

Potential consequences of an incomplete or incorrect agreement

Regulatory Action: Investigations or sanctions

Criminal Liability: Possible prosecution for improper prescribing

Loss of DEA Registration: Suspension or revocation risk

Civil Claims: Malpractice or wrongful death suits

Professional Discipline: Medical board sanctions

Patient Harm: Overdose and adverse outcomes

Core components to include in a professional agreement

A comprehensive agreement balances clinical detail, patient responsibilities, and documentation to support safe, lawful prescribing.

Medication Terms

Clearly state medication names, formulations, dose limits, daily maximums, and permitted adjustments to prevent ambiguity and ensure pharmacy compliance.

Monitoring Plan

Describe PDMP checks, urine drug testing frequency, pill counts, and appointment cadence required as conditions for ongoing prescriptions.

Refill Policy

Specify refill windows, restrictions on early refills, procedures for lost or stolen medications, and criteria for emergency supplies.

Patient Responsibilities

List obligations such as single prescriber rule, secure storage, no sharing of medication, prompt reporting of side effects, and compliance with testing.

Termination Conditions

Define noncompliance triggers (tampered tests, diversion), steps before termination, and transition plans for abrupt discontinuation when clinically necessary.

Documentation

Require signature, date, clinician name and credentials, and retention instructions; note where the signed agreement will be stored and who can access it.

Practical examples of how the agreement is used

These brief scenarios show typical uses and outcomes when the agreement is applied consistently.

Outpatient Pain Clinic

A clinic adopts a standard agreement for all opioid starts to align monitoring

The agreement sets urine screens monthly for the first three months
Consistent documentation reduced refill discrepancies and clarified termination steps for noncompliance.

Primary Care Practice

A family practice uses the form for chronic benzodiazepine therapy to document tapering plans

The agreement requires quarterly reviews and PDMP checks
Clear expectations improved adherence to appointments and facilitated safe tapering when indicated.

Frequently asked questions and practical answers

Answers to common questions about eSigning, notarization, revocation, privacy, and signature authority for Controlled Substances Agreements.

Need help? Contact support

Can a Controlled Substances Agreement be signed electronically?
Yes. Electronic signatures are generally enforceable under the ESIGN Act (15 U.S.C. ch. 96) and UETA where adopted, provided intent, consent, attribution, and reliable record retention are met. For consumer‑facing healthcare records, follow ESIGN consent disclosure requirements.
Is notarization or witnesses required for validity?
Most states do not require notarization for treatment agreements. If a state or facility policy mandates notarization or witnesses, follow those rules. For remote notarization, confirm state RON statutes before relying on remote notary services.
How can a patient revoke the agreement?
Revocation should be handled in writing; record the revocation in the EHR. Note that revocation does not obligate continued prescribing and clinicians retain professional discretion to modify or stop controlled medications.
What privacy protections apply to the agreement?
The agreement contains protected health information and must be handled under HIPAA privacy and security rules. Use encrypted storage and limit access to authorized personnel; obtain any additional consents required for disclosures.
Who is authorized to sign on behalf of a patient?
Adults must sign personally. For minors or incapacitated adults, a legally authorized representative may sign per state law; document authority (power of attorney or guardianship) in the chart.
What if the prescribing clinician changes?
Document transfer of care, update the agreement or create a new one with the incoming clinician, and ensure continuity of monitoring and refill instructions in the medical record.

be ready to get more

Join over 28 million airSlate SignNow users

Sign Now